ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Shivendra Dutt Shukla1 , Geeta Gupta1, Razia Khatoon2, Ritu Jain1 and Ankita Gupta1
1Department of Microbiology, Santosh Medical College & Hospital, Ghaziabad – 201 001, Uttar Pradesh, India.
2Department of Microbiology, Hind Institute of Medical Sciences, Sitapur – 261 303, Uttar Pradesh, India.
J Pure Appl Microbiol. 2022;16(2):858-866 | Article Number: 7398
https://doi.org/10.22207/JPAM.16.2.04 | © The Author(s). 2022
Received: 29/10/2021 | Accepted: 22/02/2022 | Published online: 12/04/2022
Issue online: June 2022
Abstract

Multidrug resistant Pseudomonas aeruginosa is an alarming and emerging public health problem globally across the developing countries. Pseudomonas aeruginosa is still a major cause for nosocomial infection and approx 10-20% of these patients are admitted to the ICU’s. Bacterial isolates those are biofilm producers are more drug resistant than biofilm Non-producers. The aim of the present study was to evaluate the production of biofilm and β-lactamases (ESBL, MBL, AmpC) in multi drug resistant Pseudomonas aeruginosa isolated from ICU patients. The present cross-sectional prospective study was carried out in the Department of Microbiology, Santosh Medical College & Hospital, Ghaziabad, Uttar-Pradesh, India. A total of 115 isolates of P. aeruginosa were isolated from 502 clinical samples.  After confirmation of MDR status of P. aeruginosa further processing for biofilm and beta lactamases was performed accordingly. Biofilm production was done by test tube method and tissue culture plate method along with phenotypic profiling of ESBL, MBL and AmpC was performed by disc potentiation test; IMP-EDTA combined disc test and Cefoxitin Cloxacillin Double Disc synergy test (CC-DDST) respectively. Out of 502 total human clinical samples 115 isolates were Pseudomonas aeruginosa giving the prevalence rate of 23%. Among 115 isolates of P. aeruginosa 60 (52%) were MDR phenotypes, Out of 60 MDR isolates 23 (38.3%) were ESBL producers, 22 (36.6%) were MBL producers, and 3(5%) were AmpC producers. Out of total 115 isolates 68(59%) isolates were biofilm producers and 47 (40.8%) were biofilm non-producers. Strict antibiotic policies with early detection of beta lactamases and detection of biofilm production should be performed regularly for all clinical isolates of Pseudomonas aeruginosa so as to guide antibiotic selection along with better management of severe infection in ICU patients.

Keywords

Extended Spectrum beta lactamases (ESBL), Metallo betalactamases (MBL), Multidrug resistant, Biofilm

Article Metrics

Article View: 38

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.